Prevalence of Genital HPV Infection in Males Following Introduction of Universal Male HPV Vaccination
Impress
1 other identifier
observational
345
1 country
1
Brief Summary
This study will examine how common HPV infection is in teenage males in Australia before and after the introduction of universal school based vaccination of males in Australia.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2014
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 2, 2013
CompletedFirst Posted
Study publicly available on registry
December 6, 2013
CompletedStudy Start
First participant enrolled
January 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 29, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 29, 2017
CompletedResults Posted
Study results publicly available
March 6, 2020
CompletedMarch 6, 2020
March 1, 2020
4 years
December 2, 2013
August 11, 2019
March 4, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Prevalence of Penile HPV Genotypes
Prevalence of penile HPV genotypes among heterosexually active young men. Percentage of participants with specific genotypes on penile samples, as detected by Linear Array. Participants provided a single penile sample.
Single study visit (one time point per participant)
Study Arms (2)
Pre-school based vaccination program (not vaccine eligible)
Young (17-19 years) men who were not eligible for school based vaccination due to their age at the time of the programs roll out.
Post-school based vaccination program (vaccine eligible)
Young men (17-19 years) who were eligible for school based vaccination due to their age at the time of the programs roll out.
Eligibility Criteria
Males aged 17-19 recruited from sexual health clinics and community sources
You may qualify if:
- Male
- Aged 17 to 19
- Able to complete study requirements
- Residing in Australia from 12 years of age
You may not qualify if:
- Males reporting sex with males in the past 12 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- The Alfredlead
- Merck Sharp & Dohme LLCcollaborator
Study Sites (1)
Melbourne Sexual Health Centre
Melbourne, Victoria, 3053, Australia
Biospecimen
Penile sampling for HPV DNA
Results Point of Contact
- Title
- A/Prof Marcus Chen
- Organization
- Melbourne Sexual Health Centre
Study Officials
- PRINCIPAL INVESTIGATOR
Marcus Y Chen, PhD
Melbourne Sexual Health Centre Alfred Health and Central Clinical School Monash University
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- observational
- Observational Model
- ECOLOGIC OR COMMUNITY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Adjunct Associate Professor Central Clinical School and Medical Services Manager Melbourne Sexual Health Centre
Study Record Dates
First Submitted
December 2, 2013
First Posted
December 6, 2013
Study Start
January 1, 2014
Primary Completion
December 29, 2017
Study Completion
December 29, 2017
Last Updated
March 6, 2020
Results First Posted
March 6, 2020
Record last verified: 2020-03